Analysts Weigh In On Pfizer After Earnings Beat And Weak 2015 Forecast

Tuesday morning, Pfizer Inc. PFE posted better than expected resultsfor the fourth quarter, but issued a weak 2015 forecast. Following the earnings call, several research firms weighed in on the results.

Morgan Stanley and Credit Suisse were amongst the first ones to comment. While the latter remains bullish, reiterating an Outperform rating and a $35 price target, the former seemed less confident, and issued an Equal-weight recommendation on the stock.

 

Credit Suisse

 

In a report published Monday morning, Credit Suisse analysts said that they “expect the stock to be down today but […] see room for PFE to outperform in 2015 given optionality from business development and/or the pipeline, inexpensive valuation, and group-high 3.4% dividend yield.”

In addition, the report pointed out two more growth drivers: “good product performance driven by innovative businesses” and “reasonable operating margins, still driven heavily by GEP.”

 

Morgan Stanley

 

Morgan Stanley’s report noted Pfizer’s above-forecast fourth quarter results, but also highlighted the 2015 EPS guidance, 6 percent below its expectations, which “reflects a $0.17 FX hit and a $0.03 impact from the planned upfront payment associated with the global R&D agreement for OPKO’s long-acting human growth hormone.”

Finally, analysts showed themselves surprised by some of the products’ (like Celebrex) sales, while mentioning several other key products that were in line with projections.

Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: Analyst ColorEarningsNewsGuidancePrice TargetReiterationAnalyst RatingsCredit SuisseMorgan Stanley
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...